1
|
|
2
|
Chrétien B, Hamel-Sénécal L, Philippe V, Lelong-Boulouard V, Micallef J, Le Boisselier R. Venlafaxine : la bébé ecstasy ? À propos de cas rapportés à 2 centres d’addictovigilance. Therapie 2018. [DOI: 10.1016/j.therap.2018.09.027] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/27/2022]
|
3
|
Paulis MG, Hafez EM, El-Tahawy NF, Aly MKM. Toxicological Assessment of Venlafaxine: Acute and Subchronic Toxicity Study in Rats. Int J Toxicol 2018; 37:327-334. [PMID: 29862856 DOI: 10.1177/1091581818777470] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Antidepressants are the most commonly prescribed drugs for psychiatric treatment, and venlafaxine (VEN) is one of the most popular options. Venlafaxine is a nontricyclic dual-acting serotonin-norepinephrine reuptake inhibitor. Although an increased incidence of acute toxicity and addiction has been reported, controlled studies examining its toxic effects on different organs are still lacking. This study investigated the possible toxic effects of VEN on the liver, kidney, and gastric tissues. Three groups of rats were administered saline, a single LD50 dose (350 mg/kg), or 100 mg/kg VEN daily, followed by increases in the dose of 50 mg/kg every 10 days for 30 days (about 10 times the therapeutic doses). The following parameters of liver and kidney injury were then assayed: alanine aminotransferase, aspartate aminotransferase, γ-glutamyl transferase, prothrombin time, partial thromboplastin time, blood urea nitrogen, and serum creatinine. A histopathological examination was then conducted. Both acute and subchronic administration of VEN produced multiple clinical manifestations in the experimental animals, including seizures, coma, and even death. Moreover, the liver and renal function tests indicated injury in these tissues. Furthermore, the histopathological examination showed signs of organ toxicity after both acute and chronic VEN exposure. This study has shown that VEN has harmful effects on the liver, kidney, and stomach in either a single high dose (LD50) or repeated exposure to 10 times the therapeutic doses. As a result, strategies to increase awareness of these effects among physicians and the public are needed because this drug may be addictive.
Collapse
Affiliation(s)
- Melad G Paulis
- 1 Forensic Medicine and Clinical Toxicology Department, Faculty of Medicine, Minia University, Menia, Egypt
| | - Essam M Hafez
- 1 Forensic Medicine and Clinical Toxicology Department, Faculty of Medicine, Minia University, Menia, Egypt
| | - Nashwa F El-Tahawy
- 2 Department of Histology and Cell Biology, Faculty of Medicine, Minia University, Menia, Egypt
| | - Mohmed K M Aly
- 3 Psychiatry Department, Faculty of Medicine, Minia University, Menia, Egypt
| |
Collapse
|
4
|
Schifano F, Chiappini S, Corkery JM, Guirguis A. Abuse of Prescription Drugs in the Context of Novel Psychoactive Substances (NPS): A Systematic Review. Brain Sci 2018; 8:E73. [PMID: 29690558 PMCID: PMC5924409 DOI: 10.3390/brainsci8040073] [Citation(s) in RCA: 48] [Impact Index Per Article: 8.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/27/2018] [Revised: 04/11/2018] [Accepted: 04/20/2018] [Indexed: 02/07/2023] Open
Abstract
Recently, a range of prescription and over-the-counter drugs have been reportedly used as Novel Psychoactive Substances (NPS), due to their potential for abuse resulting from their high dosage/idiosyncratic methods of self-administration. This paper provides a systematic review of the topic, focusing on a range of medications which have emerged as being used recreationally, either on their own or in combination with NPS. Among gabapentinoids, pregabalin may present with higher addictive liability levels than gabapentin, with pregabalin being mostly identified in the context of opioid, polydrug intake. For antidepressants, their dopaminergic, stimulant-like, bupropion activities may explain their recreational value and diversion from the therapeutic intended use. In some vulnerable clients, a high dosage of venlafaxine (‘baby ecstasy’) is ingested for recreational purposes, whilst the occurrence of a clinically-relevant withdrawal syndrome may be a significant issue for all venlafaxine-treated patients. Considering second generation antipsychotics, olanzapine appears to be ingested at very large dosages as an ‘ideal trip terminator’, whilst the immediate-release quetiapine formulation may possess proper abuse liability levels. Within the image- and performance- enhancing drugs (IPEDs) group, the beta-2 agonist clenbuterol (‘size zero pill’) is reported to be self-administered for aggressive slimming purposes. Finally, high/very high dosage ingestion of the antidiarrhoeal loperamide has shown recent increasing levels of popularity due to its central recreational, anti-withdrawal, opiatergic effects. The emerging abuse of prescription drugs within the context of a rapidly modifying drug scenario represents a challenge for psychiatry, public health and drug-control policies.
Collapse
Affiliation(s)
- Fabrizio Schifano
- Psychopharmacology, Drug Misuse and Novel Psychoactive Substances Research Unit, School of Life and Medical Sciences, University of Hertfordshire, Hertfordshire AL10 9AB, UK.
| | - Stefania Chiappini
- Psychopharmacology, Drug Misuse and Novel Psychoactive Substances Research Unit, School of Life and Medical Sciences, University of Hertfordshire, Hertfordshire AL10 9AB, UK.
| | - John M Corkery
- Psychopharmacology, Drug Misuse and Novel Psychoactive Substances Research Unit, School of Life and Medical Sciences, University of Hertfordshire, Hertfordshire AL10 9AB, UK.
| | - Amira Guirguis
- Psychopharmacology, Drug Misuse and Novel Psychoactive Substances Research Unit, School of Life and Medical Sciences, University of Hertfordshire, Hertfordshire AL10 9AB, UK.
| |
Collapse
|
5
|
Anderson LS, Bell HG, Gilbert M, Davidson JE, Winter C, Barratt MJ, Win B, Painter JL, Menone C, Sayegh J, Dasgupta N. Using Social Listening Data to Monitor Misuse and Nonmedical Use of Bupropion: A Content Analysis. JMIR Public Health Surveill 2017; 3:e6. [PMID: 28148472 PMCID: PMC5311422 DOI: 10.2196/publichealth.6174] [Citation(s) in RCA: 35] [Impact Index Per Article: 5.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/10/2016] [Revised: 11/02/2016] [Accepted: 01/07/2017] [Indexed: 12/17/2022] Open
Abstract
Background The nonmedical use of pharmaceutical products has become a significant public health concern. Traditionally, the evaluation of nonmedical use has focused on controlled substances with addiction risk. Currently, there is no effective means of evaluating the nonmedical use of noncontrolled antidepressants. Objective Social listening, in the context of public health sometimes called infodemiology or infoveillance, is the process of identifying and assessing what is being said about a company, product, brand, or individual, within forms of electronic interactive media. The objectives of this study were (1) to determine whether content analysis of social listening data could be utilized to identify posts discussing potential misuse or nonmedical use of bupropion and two comparators, amitriptyline and venlafaxine, and (2) to describe and characterize these posts. Methods Social listening was performed on all publicly available posts cumulative through July 29, 2015, from two harm-reduction Web forums, Bluelight and Opiophile, which mentioned the study drugs. The acquired data were stripped of personally identifiable identification (PII). A set of generic, brand, and vernacular product names was used to identify product references in posts. Posts were obtained using natural language processing tools to identify vernacular references to drug misuse-related Preferred Terms from the English Medical Dictionary for Regulatory Activities (MedDRA) version 18 terminology. Posts were reviewed manually by coders, who extracted relevant details. Results A total of 7756 references to at least one of the study antidepressants were identified within posts gathered for this study. Of these posts, 668 (8.61%, 668/7756) referenced misuse or nonmedical use of the drug, with bupropion accounting for 438 (65.6%, 438/668). Of the 668 posts, nonmedical use was discouraged by 40.6% (178/438), 22% (22/100), and 18.5% (24/130) and encouraged by 12.3% (54/438), 10% (10/100), and 10.8% (14/130) for bupropion, amitriptyline, and venlafaxine, respectively. The most commonly reported desired effects were similar to stimulants with bupropion, sedatives with amitriptyline, and dissociatives with venlafaxine. The nasal route of administration was most frequently reported for bupropion, whereas the oral route was most frequently reported for amitriptyline and venlafaxine. Bupropion and venlafaxine were most commonly procured from health care providers, whereas amitriptyline was most commonly obtained or stolen from a third party. The Fleiss kappa for interrater agreement among 20 items with 7 categorical response options evaluated by all 11 raters was 0.448 (95% CI 0.421-0.457). Conclusions Social listening, conducted in collaboration with harm-reduction Web forums, offers a valuable new data source that can be used for monitoring nonmedical use of antidepressants. Additional work on the capabilities of social listening will help further delineate the benefits and limitations of this rapidly evolving data source.
Collapse
Affiliation(s)
| | - Heidi G Bell
- Gyra MediPharm ConsultingResearch Triangle Park, NCUnited States
| | | | | | | | - Monica J Barratt
- National Drug and Alcohol Research Centre, UNSW AustraliaRandwickAustralia.,Bluelight.orgDover, DEUnited States.,Kadiant AnalyticsBoston, MAUnited States
| | - Beta Win
- GlaxoSmithKlineStockley Park, MiddlesexUnited Kingdom
| | | | | | | | | |
Collapse
|
6
|
Francesconi G, Orsolini L, Papanti D, Corkery JM, Schifano F. Venlafaxine as the 'baby ecstasy'? Literature overview and analysis of web-based misusers' experiences. Hum Psychopharmacol 2015. [PMID: 26216559 DOI: 10.1002/hup.2476] [Citation(s) in RCA: 11] [Impact Index Per Article: 1.2] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/08/2022]
Abstract
INTRODUCTION Venlafaxine is one of the most frequently prescribed antidepressants worldwide, despite its toxicity risk in overdose. Furthermore, the molecule has been recently identified at the EU-wide level as one of the novel psychoactive substances. This paper aims at investigating the potential of misuse, taking into account both the existing literature and the analysis of the misusers' experiences as described in venlafaxine misuse web reports. METHODS A literature search was performed using PubMed, Embase, and Medline. Posts/threads relating to venlafaxine misuse issues were identified through Google® and Yahoo® English-language searches. Resulting websites' data were then qualitatively assessed, and information was collected on a range of issues, including dosage, drug intake modalities, untoward drug effects, and association with other recreational drugs. RESULTS A few literature case reports focusing on venlafaxine as a misusing drug were here identified. The molecule was here typically ingested or snorted at dosages up to 10-15 times higher than those clinically advised, obtaining MDMA/amphetamine-like stimulant and psychedelic effects. Polydrug misuse was commonly reported. Venlafaxine appeared to be widely available online for sale. CONCLUSIONS Physicians should carefully evaluate patients for history of drug dependence and observe them for signs of venlafaxine misuse.
Collapse
Affiliation(s)
- Giulia Francesconi
- Academic Department of Experimental and Clinical Medicine, Polytechnic University of Marche, Ancona, Italy.,School of Life and Medical Sciences, University of Hertfordshire, Hatfield, Herts, UK
| | - Laura Orsolini
- Academic Department of Experimental and Clinical Medicine, Polytechnic University of Marche, Ancona, Italy.,School of Life and Medical Sciences, University of Hertfordshire, Hatfield, Herts, UK
| | - Duccio Papanti
- Medical School of Trieste, Italy.,School of Life and Medical Sciences, University of Hertfordshire, Hatfield, Herts, UK
| | - John M Corkery
- School of Life and Medical Sciences, University of Hertfordshire, Hatfield, Herts, UK
| | - Fabrizio Schifano
- School of Life and Medical Sciences, University of Hertfordshire, Hatfield, Herts, UK
| |
Collapse
|
7
|
Abstract
BACKGROUND Rates of prescription drug abuse have reached epidemic proportions. Large-scale epidemiologic surveys of this under-recognized clinical problem have not included antidepressants despite their contribution to morbidity and mortality. The purpose of this review is to look specifically at the misuse of antidepressants and how this behavior may fit into the growing crisis of nonmedical use of prescription drugs. METHODS We conducted a comprehensive search on PubMed, Medline, and PsycINFO using the search terms "antidepressant", "abuse", "misuse", "nonmedical use", "dependence", and "addiction", as well as individual antidepressant classes (eg, "SSRI") and individual antidepressants (eg, "fluoxetine") in various combinations, to identify articles of antidepressant misuse and abuse. RESULTS A small but growing literature on the misuse and abuse of antidepressants consists largely of case reports. Most cases of antidepressant abuse have occurred in individuals with comorbid substance use and mood disorders. The most commonly reported motivation for abuse is to achieve a psychostimulant-like effect. Antidepressants are abused at high doses and via a variety of routes of administration (eg, intranasal, intravenous). Negative consequences vary based upon antidepressant class and pharmacology, but these have included seizures, confusion, and psychotic-like symptoms. CONCLUSION The majority of individuals prescribed antidepressants do not misuse the medication. However, certain classes of antidepressants do carry abuse potential. Vulnerable patient populations include those with a history of substance abuse and those in controlled environments. Warning signs include the presence of aberrant behaviors. Physicians should include antidepressants when screening for risky prescription medication use. When antidepressant misuse is detected, a thoughtful treatment plan, including referral to an addiction specialist, should be developed and implemented.
Collapse
Affiliation(s)
- Elizabeth A Evans
- Department of Psychiatry, Columbia University College of Physicians and Surgeons, New York, NY, USA
| | - Maria A Sullivan
- Department of Psychiatry, Columbia University College of Physicians and Surgeons, New York, NY, USA
| |
Collapse
|
8
|
McKee J, Penn JV, Koranek A. Psychoactive Medication Misadventuring in Correctional Health Care. JOURNAL OF CORRECTIONAL HEALTH CARE 2014; 20:249-260. [PMID: 24934843 DOI: 10.1177/1078345814532419] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/15/2022]
Abstract
Due to multiple factors, unprecedented numbers of individuals with mental health disorders and many with comorbid substance use disorders are now incarcerated in jails and prisons. This article details a variety of medication use and potential abuse/misuse/misadventuring topics that are unique to the correctional health care setting, with emphasis on how the large number of persons with psychiatric and/or substance use disorders affects these issues and methods that correctional systems commonly use to manage these inmate-patients. Also discussed are the potential for inmate feigning or malingering as a goal-directed behavior, potential for misadventuring/abuse of commonly used medications, urine drug screening/surveillance, and the effect of psychoactive medications on heat tolerance and environmental issues.
Collapse
Affiliation(s)
- Jerry McKee
- Community Care of North Carolina, Raleigh, NC, USA
| | - Joseph V Penn
- University of Texas Medical Branch Correctional Managed Care, Huntsville, TX, USA
| | - Angela Koranek
- University of Texas Medical Branch Correctional Managed Care, Huntsville, TX, USA
| |
Collapse
|
9
|
Namdari B. Venlafaxine Abuse in a Patient with Schizophrenia and Prior History of Substance Dependence: A Case Report. J Addict Dis 2013; 32:393-5. [DOI: 10.1080/10550887.2013.849974] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/26/2022]
|
10
|
Abstract
The use of antidepressants for alcoholism in humans has been a matter of controversy in recent years. Despite the existence of an important co-morbidity for depression and alcoholism, some studies suggest that the use of antidepressants could worsen the prognosis of alcoholism. However, there is a lack of studies in animal models exploring this phenomenon. In the present study, we show how the 15-d treatment with fluoxetine (10 mg/kg) or venlafaxine (50 mg/kg) affected alcohol deprivation effect (ADE) and subsequent alcohol consumption. Initially, fluoxetine reduced ADE and venlafaxine did not affect it. However, in the following days, both antidepressants increased alcohol consumption, an effect that was found to last at least 5 wk. Fluoxetine treatment was shown to cause a locomotor sensitized response to a challenge dose of amphetamine (0.5 mg/kg), indicating the presence of a supersensitive dopaminergic transmission. In summary, antidepressant treatment may increase alcohol consumption in rats after a period of alcohol deprivation and this could be related to alterations in the reward circuitry. This finding confirms in an animal model previous reports in humans that may limit the use of antidepressants for alcoholism.
Collapse
|
11
|
McKee J. Frequently asked questions (FAQ) regarding medication use and abuse in correctional healthcare settings. Ment Health Clin 2012. [DOI: 10.9740/mhc.n95630] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
Affiliation(s)
- Jerry McKee
- Associate Director of Behavioral Health Pharmacy Programs, Community Care of North Carolina, Raleigh, North Carolina
| |
Collapse
|
12
|
Song JH, Yu BH, Lee D, Yoon SC, Jeon HJ. Uncontrolled self-medication with venlafaxine in a patient with major depressive disorder. Psychiatry Investig 2011; 8:74-6. [PMID: 21519542 PMCID: PMC3079191 DOI: 10.4306/pi.2011.8.1.74] [Citation(s) in RCA: 6] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 03/03/2010] [Revised: 10/25/2010] [Accepted: 10/27/2010] [Indexed: 11/19/2022] Open
Abstract
Antidepressants are known to have no significant ability to cause addiction. However, a recent study showed many individuals with mood disorders self-medicated with antidepressants to relieve symptoms. We report here a male physician, diagnosed five years ago with major depressive disorder, with insomnia, anxiousness, and chest heaviness. He began self-medicating with 150 mg of venlafaxine daily, without any monitoring. During his most recent severe depressive episode, he was taking up to 1,500 mg of venlafaxine daily. Without this medication, he experienced discontinuation syndrome, which included severe anxiety, chest heaviness, and breathing difficulty, and which he judged as indicating a more severely depressed state. He also experienced overdose symptoms, such as hypertension and tachycardia. He attempted suicide with drugs that he possessed. In conclusion, careful monitoring is needed when treating patients with venlafaxine, because its discontinuation syndrome is similar to symptoms of major depressive disorder, and suicidality may result from an overdose.
Collapse
Affiliation(s)
- Ji-Hye Song
- Department of Psychiatry, Depression Center, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea
| | - Bum-Hee Yu
- Department of Psychiatry, Depression Center, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea
| | - Dongsoo Lee
- Department of Psychiatry, Depression Center, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea
| | - Se Chang Yoon
- Department of Psychiatry, Depression Center, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea
| | - Hong Jin Jeon
- Department of Psychiatry, Depression Center, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea
| |
Collapse
|
13
|
Quaglio G, Schifano F, Lugoboni F. Venlafaxine dependence in a patient with a history of alcohol and amineptine misuse. Addiction 2008; 103:1572-4. [PMID: 18636997 DOI: 10.1111/j.1360-0443.2008.02266.x] [Citation(s) in RCA: 11] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/27/2022]
Abstract
BACKGROUND Venlafaxine is an inhibitor of neuronal serotonin and noradrenaline re-uptake and a weak inhibitor of dopamine re-uptake. There was no indication of problems of abuse/dependence during the clinical trials. CASE DESCRIPTION A 53-year-old client with a history of alcohol and amineptine misuse and a long history of recurrent depression, for which he was prescribed venlafaxine tablets. Over time, he increased the dosage to 50 tablets daily (3750 mg). Large venlafaxine dosages produced amphetamine-like effects, due possibly to the related increase in dopamine turnover. Once hospitalized for detoxification, the patient had a symptomatology which was consistent with a serotonergic discontinuation syndrome. CONCLUSIONS Physicians should be aware that patients with a history of drug and alcohol abuse might develop venlafaxine dependence.
Collapse
Affiliation(s)
- Gianluca Quaglio
- Medical Service for Addictive Disorders, Department of Internal Medicine, University of Verona, Policlinico G.B. Rossi, Verona, Italy.
| | | | | |
Collapse
|